HopeStage
Back to all studies
CompletedNCT01397786

Long-Term OPC-34712 Safety as Maintenance Treatment for Schizophrenia

About this titleRead the official source — NCT01397786

Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 147 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2011
Recruitment status
Completed
Enrollment listed in the registry
1,044
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada, Colombia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01397786
Official title
Show the full official title

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Little Rock, United States · Springdale, United States

126 more locations
  • Anaheim, United States
  • Cerritos, United States
  • Escondido, United States
  • Garden Grove, United States
  • Glendale, United States
  • Long Beach, United States
  • National City, United States
  • Oakland, United States
  • Oceanside, United States
  • Pico Rivera, United States
  • San Diego, United States
  • Torrance, United States
  • Washington D.C., United States
  • Bradenton, United States
  • Leesburg, United States
  • Maitland, United States
  • Miami, United States
  • Miami Springs, United States
  • North Miami, United States
  • Tampa, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Joliet, United States
  • Oak Brook, United States
  • Overland Park, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Flowood, United States
  • Saint Charles, United States
  • St Louis, United States
  • Las Vegas, United States
  • Buffalo, United States
  • Cedarhurst, United States
  • Jamaica, United States
  • Rochester, United States
  • Staten Island, United States
  • Dayton, United States
  • Allentown, United States
  • Norristown, United States
  • Charleston, United States
  • Memphis, United States
  • Austin, United States
  • Dallas, United States
  • Houston, United States
  • Richmond, United States
  • Kirkland, United States
  • Burlington, Canada
  • Chatham, Canada
  • Barranquilla, Colombia
  • Bello, Colombia
  • Bogotá, Colombia
  • Pereira, Colombia
  • Rijeka, Croatia
  • Zagreb, Croatia
  • Fujisawa-shi, Japan
  • Kumamoto, Japan
  • Kunigami-gun, Japan
  • Sakai-shi, Japan
  • Daugavpils, Latvia
  • Jelgava, Latvia
  • Liepāja, Latvia
  • Riga, Latvia
  • Strenči, Latvia
  • Kota Bharu, Malaysia
  • Kuala Lumpur, Malaysia
  • Kajang, Malaysia
  • Ipoh, Malaysia
  • Jalan Greentown, Malaysia
  • Sabak Bernam, Malaysia
  • Col. Florida, Mexico
  • Monterrey, Mexico
  • San Luis Potosí City, Mexico
  • Cebu City, Philippines
  • Davao City, Philippines
  • Manila, Philippines
  • Choroszcz, Poland
  • Gdansk, Poland
  • Lodz, Poland
  • San Juan, Puerto Rico
  • Arad, Romania
  • Brasov, Romania
  • Bucharest, Romania
  • Cluj-Napoca, Romania
  • Craiova, Romania
  • Focşani, Romania
  • Iași, Romania
  • Piteşti, Romania
  • Targoviste, Romania
  • Arkhangelsk, Russia
  • Moscow, Russia
  • Moscow Region, Russia
  • Nizhny Novgorod, Russia
  • Petrozavodsk, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Saratov, Russia
  • Tomsk, Russia
  • Village Nikolskoe, Russia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Novi Kneževac, Serbia
  • Novi Sad, Serbia
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavská Sobota, Slovakia
  • Rožňava, Slovakia
  • Incheon, South Korea
  • Seoul, South Korea
  • Kashsiung, Taiwan
  • New Taipei City, Taiwan
  • Taipei, Taiwan
  • Taoyuan County, Taiwan
  • Diyarbakır, Türkiye
  • Kocaeli, Türkiye
  • Chernihiv, Ukraine
  • Dnipropetrovsk, Ukraine
  • Hlevakha, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Vil. Stepanivka, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Simferopol, Ukraine
  • Vinnytsia, Ukraine
  • Russia
  • Türkiye

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including OPC-34712.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies